{"schema_version":"secwatch.filing_event.v1","accession":"0001665988-25-000025","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.080022+00:00","generated_at":"2026-05-17T00:39:03.038858+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M","bullets":["GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.","Non-GAAP EPS $0.15, up 200% from $0.05; Adjusted EBITDA $26.6M (+12.9%) with margin 19.2%.","Organic revenue growth 8.2% led by Pain Treatments (+6.4%) and Surgical Solutions (+9.3%).","Cash from operations $30.1M, +192% YoY; reaffirms FY2025 revenue $560-570M and Adj. EBITDA $112-116M.","Entered new credit agreement with $300M term loan and $100M revolver, reducing annual interest by ~$2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001665988-25-000025","json":"https://secwatch.observer/filing/0001665988-25-000025.json","markdown":"https://secwatch.observer/filing/0001665988-25-000025.md","text":"https://secwatch.observer/filing/0001665988-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000166598825000025/0001665988-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000166598825000025/bvs-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:39:03.038858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}